Citations

Clear

16280 citation(s) found for "Yu, David".

Meniscal Repair in the Setting of Revision Anterior Cruciate Ligament Reconstruction: 6-Year Follow-up Results From the MARS Cohort
Group;, MARS, Fox, Jake A. , Huston, Laura J. , Haas, Amanda K. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Amendola, Annunziato , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M. , Creighton, R. Alexander , Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C., Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCormack, Robert G. , Miller, Bruce S., Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Shea, Kevin G. , Slauterbeck, James R., Smith, Matthew V. , Svoboda, Col. Steven J., Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Williams, James S., Wolcott, Michelle L., York, James J. , Wright, Rick W. , Svoboda, Steven J. , Group;, MARS, Pennings, Jacquelyn S. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J., Brophy, Robert H. , Carpenter, James E., Cox, Charles L. , David, Tal S. , Flanigan, David C. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Kaeding, Christopher C. , Marx, Robert G. , McAllister, David R. , McCarty, Eric C. , Miller, Bruce S., Owens, Brett D. , Sherman, Orrin H. , Spang, Jeffrey T. , Vidal, Armando F. , Wolf, Brian R.

Mayo Clinic

The American Journal of Sports Medicine | November 12, 2025 | Volume: 53 | Issue: 14 | Pages: 3435-3445

10.1177/03635465251387333 | PMID 41220248 Get It

Background: Meniscal preservation has been demonstrated to contribute to long-term knee health and has been a successful intervention in isolation and in patients with anterior cruciate ligament reconstruction (ACLR). The long-term results of meniscal repair in the setting of revision ACLR have yet to be documented. Purpose: To report the incidence of meniscal repair failures at the 6-year follow-up in a cohort of patients who underwent concurrent revision ACLR and primary meniscal repair. Study Design: Prospective cohort study; Level of evidence, 2. Methods: All revision ACLRs with concomitant primary meniscal repair cases from a multicenter group between 2006 and 2011 were selected. Six-year follow-up was obtained to determine whether any subsequent surgery had occurred since their initial revision ACLR. If so, operative reports were obtained, whenever possible, to verify pathological condition and treatment. Results: In total, 221 patients from 1234 revision ACLRs underwent concurrent primary meniscal repairs (18% of the cohort). There were 238 repairs performed: 173 medial and 65 lateral. The majority of these repairs (n = 181; 76%) were performed with an all-inside technique. Six-year surgical follow-up was obtained in 77% (171/221) of the cohort, or 189 of 238 (79%) of the repairs (136 medial, 53 lateral). The meniscal repair failure rate, defined as reoperation, was 16% (31/189) at 6 years. Of the 31 failures, 28 were medial (24 all-inside, 4 inside-out; 28/136 = 20.6% failure rate) and 3 were lateral (2 all-inside, 1 inside-out; 3/53 = 5.7% failure rate). Three medial failures were treated in conjunction with a subsequent repeat revision ACLR. Medial tears underwent reoperation for failure at a significantly higher rate than lateral tears (20.6% vs 5.7%; P = .01) and had a significantly shorter survival time compared with lateral tears ( P = .02). No difference was found between the failure and nonfailure groups when it came to tear type, tear length, repair technique utilized, suture/implant type, or number of sutures used between the 2 groups. Conclusion: Meniscal repair in the revision ACLR setting has a 16% failure rate at 6 years. Failure rates for medial tears (20.6%) were found to be higher than that for lateral tears (5.7%), which aligns with previous studies in both the revision and primary ACLR setting.
DDX3X syndrome: a multicenter genotype-phenotype study
Coci, Emanuele G. , Millan, Pilar Chacon, ́Agostino, Maria Daniela D, Russell, Laura, Benamor, Mohammed Larbi , Domingo, Ana Jiménez de , Nosková, Lenka , Chapman, Kimberly A. , El‐Hattab, Ayman W. , McLeod, Scott , López‐González, Vanesa , Spataro, Nino , Manso, Carmen, Srour, Myriam , Alsubhi, Sarah, Renaud, Deborah L. , Baethmann, Martina , Wagner, Mathias, Rosenfeld, Jill A., Ahmed, Syed A. , Rawson, Kristyn L., Joensen, Fróði, Tessarech, Marine, Proteau, Clement, Hashemi‐Gorji, Feyzollah , Chatron, Nicolas, Laffargue, Fanny , Pironi, Virginia , Tania, Cruz Marino, Ricard, Jessica, Hammer, Trine Bjørg , Mariani, Milena , Torella, Annalaura, Morleo, Manuela, El-Hattab, Ayman W , Gertzen, Christoph G. W. , Millan, Pilar Chacon , Amor, Mouna Ben , Fernández‐Jaén, Alberto , Magner, Martin , Parikh, Sumit , Goel, Himanshu , Bertini, Enrico , Zanni, Ginevra , Khan, Arif , Amor, David J. , Innes, A. Micheil , Ballesta‐Martínez, María Juliana , Piccione, Maria , Salzano, Emanuela , Wagner, Mathias, Prieto‐Matos, Pablo , Rosenfeld, Jill A. , Scott, Daryl A , Tessarech, Marine , Li, Hong , Michelson, David Joshua , Putoux, Audrey , Chatron, Nicolas , Creveaux, Isabelle , Jamra, Rami Abou , Esch, Hilde Van , Ricard, Jessica, Valenzuela, Irene , Lasa‐Aranzasti, Amaia , Cueto‐González, Anna M. , Reina, Purificación Marín , Martı́nez, Francisco , Ciaccio, Claudia , D’Arrigo, Stefano , Torella, Annalaura , Nigro, Vincenzo , Morleo, Manuela , Østergaard, Elsebet , Gohlke, Holger , Palomares‐Bralo, María , Santos Simarro, Fernando

Mayo Clinic

No container title available | November 11, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7842722/v1 Get It

Abstract DDX3X dysfunction causes an X-linked multisystem disorder with high penetrance and variable expressivity. The phenotypic spectrum spans from learning disability without somatic involvement to profound intellectual disability with severe impairments in the central nervous system and other organs. A few multicenter studies and single case reports have previously highlighted some common phenotypic patterns but were unable to delineate correlations between underlying DDX3X variants and phenotypic findings.From the second largest patient cohort published to date, we analysed clinical, psychometric and diagnostic findings of 52 female and 7 male individuals, harbouring de novo and inherited DDX3X variants. These female patients revealed previously unknown quantitative correlations between variant type and localization and specific phenotypic findings (growth features, epilepsy, brain anomalies, dysmorphisms, motor-focused neurological findings). Moreover, by analysing the in silico folding and RNA binding capability of mutant DDX3X monomers, we were able to delineate novel correlations between DDX3X monomer misfolding grade and phenotypic severity.
Liquid biopsy for very early detection of HPV-associated oropharyngeal cancer
Hidalgo, Axel , Chaudhuri, Aadel A. , Routman, David M , Hidalgo, Axel M , Chaudhuri, Aadel A , Routman, David M.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 11, 2025 | Volume: 118 | Issue: 1 | Pages: 7-9

10.1093/jnci/djaf302 | PMID 41217389 Get It

Drug Repurposing for Reducing the Size of Benign Thyroid Nodules: A Systematic Review
Jacome, Cristian Soto , Arce-Camposano, Andrea, Toro-Tobón, David , Zahidy, Misk Al, Rivadeneira, Francisco, Fierro, Francisco E, Montero, Marcelo, Ospina, Naykky Singh , Soto Jacome, Cristian , Al Zahidy, Misk, Ponce, Oscar, Singh Ospina, Naykky , Brito, Juan P , Toro-Tobon, David , Rivadeneira, Francisco, Fierro, Francisco Emilio , Montero, Marcelo, Ponce, Oscar J. , Brito, Juan P.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | November 11, 2025 | Volume: 111 | Issue: 2 | Pages: e327-e338

10.1210/clinem/dgaf616 | PMID 41225692 Get It

Abstract Context Benign thyroid nodules (BTNs) are highly prevalent, and current treatment options are primarily invasive. There is a need for effective, noninvasive alternatives. Objective To systematically evaluate the efficacy of repurposed pharmacologic agents in reducing the size of BTNs. Data Sources MEDLINE, EMBASE, Cochrane databases, and Scopus were searched from inception to December 18, 2024. Study Selection We included preclinical and clinical studies evaluating repurposed drugs for BTNs in adults. Of 1499 records screened, 20 studies met inclusion criteria: 6 randomized controlled trials (RCTs), 6 prospective cohorts, 3 retrospective observational studies, 3 case reports, 1 cross-sectional study, and 1 preclinical study. Data Extraction Data were extracted independently in duplicate using a standardized form. Data Synthesis Narrative synthesis was conducted due to heterogeneity. Metformin was the most frequently evaluated agent (7 studies), with 5 studies (including 2 RCTs) reporting statistically significant reductions in dominant nodule volume. One prospective study demonstrated a reduction in the maximum nodule diameter, which was not statistically significant, and 1 RCT showed no changes in nodule size after intervention. Statins (4 studies) and somatostatin analogues (4 studies) showed mixed results. Myo-inositol with selenium, herbal formulations, and immune checkpoint inhibitors showed promise in single studies or case reports. Conclusion Metformin shows the most consistent potential for noninvasive reduction of BTN size, particularly in patients with metabolic comorbidities. However, current evidence is limited and heterogeneous. Further large-scale studies are needed to confirm efficacy and guide clinical use.
Review Article: The Evolving Role of GLP ‐1 Receptor Agonists in Gastroenterology Practice
Pomenti, Sydney , Gerber, Annabel, Katzka, David A. , Camilleri, Michael , Hur, Chin , Katzka, D A

Mayo Clinic

Alimentary Pharmacology & Therapeutics | November 11, 2025 | Volume: 63 | Issue: 2 | Pages: 203-209

10.1111/apt.70450 | PMID 41215723 Get It

ABSTRACT Background Obesity affects over 40% of the US population and contributes to worse outcomes in a variety of diseases and disorders. Glucagon‐like peptide‐1 receptor agonists have drawn attention for their impact on obesity. With a dense population of receptors throughout the gastrointestinal tract, it is critical to understand the way that glucagon‐like peptide‐1 receptor agonists impact gastrointestinal diseases and disorders. Aims To evaluate the expanding role of glucagon‐like peptide‐1 receptor agonists in the management of obesity and gastrointestinal disease, with a focus on therapeutic applications, impact on gastrointestinal cancers, safety profile, and implications for gastroenterology practice. Methods We conducted a narrative review of recent clinical trials, cohort studies, and guideline updates through 2025. Evidence was synthesised on efficacy, safety, and clinical implications across gastrointestinal disorders including steatotic liver disease, gastroesophageal reflux, inflammatory bowel disease, short bowel syndrome, and obesity‐associated cancers. Results Glucagon‐like peptide‐1 receptor agonists induce substantial and durable weight loss and improve obesity‐related gastrointestinal outcomes. They are approved for steatotic liver disease, with demonstrated histologic and biochemical benefits. Evidence suggests a reduced incidence of several gastrointestinal cancers. The most common adverse events include nausea, vomiting, diarrhoea, constipation, and delayed gastric emptying, which may affect peri‐endoscopic management. Discontinuation rates remain substantial but can be mitigated by careful titration and specialist oversight. Conclusions Glucagon‐like peptide‐1 receptor agonists are a critical therapy for obesity and several related gastrointestinal conditions. Gastroenterologists are uniquely positioned to optimize their use, manage adverse events, coordinate multidisciplinary care, and ensure safe and effective integration into practice.
TMIC-113. An Alzheimer’s neuroinflammatory microenvironment resists glioblastoma immune hijacking
Nascari, David , Eghlimi, Ryan , Grief, Dustin, Haug, Katelin, Alton, Drake, Fryer, John Denis , Tran, Nhan L. , Tran, Nhan L , Beniwal, Angad , Bouchal, Samantha M.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v471-v471

10.1093/neuonc/noaf201.1867 Get It

Abstract Glioblastoma (GBM) and Alzheimer’s disease (AD) are devastating, age associated disorders with no cure. Epidemiologic data has established an inverse comorbidity between AD and cancer, including GBM, with up to a 50% reduction of cancer incidence in AD patients. While the underlying biology remains unclear, myeloid cells, which are central players in both neurodegeneration and tumor immunity, may serve as a mechanistic link. We hypothesize that myeloid cells activated by pre-existing AD pathology suppress tumor growth more effectively than homeostatic microglia. In this study, age-matched APPNL-G-F/MAPT double knock-in (henceforth “AD”) and wildtype (WT) mice received orthotopic xenografts of syngeneic GBM cell lines (GL261, SB28) (n=15/sex/genotype). We observed a significant survival difference, with AD mice living an average of 20% longer than WT mice (p<0.0001). In vivo luciferase imaging revealed impaired engraftment of tumor cells in AD mice compared to WT a week post-engraftment (p<0.05). At the microscopic level, tumors in AD mice were found to have nearly 2-fold the amount of tumor-infiltrating myeloid cells (p<0.01), with the proportion of anti-tumoral “activated” myeloid cells also being greater (p<0.05). Tumors in AD mice were found to have markedly higher immune infiltrate at the tumor rim and margin (p<0.001). We also observed striking astrogliosis (GFAP+) and microgliosis (P2RY12+) in both the tumor rim (p<0.05) and margin (p<0.01) in AD animals. This robust glial response was significantly higher in AD mice bearing tumor compared to both WT mice bearing tumor and sham AD mice. Lastly, we utilized a luciferase stain to visualize tumor cells that invaded beyond the bulk tumor. We found that both the quantity (p<0.01) and invasion distance of tumor cells (p<0.05) was lower in AD mice. We demonstrate that an AD-induced inflammatory microenvironment antagonizes glioma growth, providing a foundation for novel GBM treatment strategies that potentially exploit these immune signals.
TMET-56. Targeting transsulfuration via suppression of thyroid hormone signaling: a modified phase 1/2 and pharmacodynamic trial of methimazole in patients with progressive WHO grade 4 gliomas
Ponti, András K. , Angelov, Lilyana , Barnett, Gene H. , Hage, Lea El , Grabowsky, Matthew, Hufsey, Rachel, Lobbous, Mina , Malkin, Mark G. , Mohammadi, Alireza M. , Silver, Daniel J. , Stevens, Glen , Torres-Trejo, Alejandro, Lathia, Justin D. , Peereboom, David M. , Yang, Kailin , Cordova, Christine , Dhawan, Andrew , Soni, Pranay , Hine, Christopher

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v441-v441

10.1093/neuonc/noaf201.1747 Get It

Abstract BACKGROUND Gaseous hydrogen sulfide (H2S), a by-product of cysteine metabolism, inhibits cancer cell behavior and growth in glioblastoma (GBM) models. H2S production capacity (HPC) is decreased in human GBM specimens compared to non-tumor controls. Thus, boosting HPC is a novel strategy for GBM treatment. Suppression of thyroid hormone signaling increases production of H2S. Hypothesis: methimazole-induced hypothyroidism will increase tumor HPC to enhance chemotherapy efficacy in GBM. GOAL Proof of concept that methimazole, by reducing thyroid hormone signaling, can increase HPC in patients with recurrent/progressive GBM (rGBM). PRIMARY ENDPOINTS 10% increase in HPC and a 1.5-fold increase in peripheral blood sulfhydration signaling. METHODS This window of opportunity trial evaluates safety, HPC in plasma and tumor, and efficacy of methimazole + chemotherapy in patients with rGBM. rGBM patients planned for a resection begin methimazole 15 mg/d 5-7 days pre-op with investigator’s choice chemotherapy added 10-28 days post-op. Patients receive combination until progression. Pre- and post-op plasma and resected tumor tissue are assayed for HPC and proteins relevant to H2S production. Key eligibility: rGBM for whom a clinically-indicated resection is planned; normal thyroid function with no history of thyroid dysfunction. Patients may have received unlimited prior regimens including bevacizumab. RESULTS To date 15 patients (8 male), median age 56 years, enrolled. The trial was amended to increase methimazole to 25 mg/d; 3 patients have received this dose. Median TSH rose from 1.3 mU/ml to 20.5 at cycle 6. Free T3 and T4 did not fall significantly. Median plasma HPC rose 3-fold while tumor HPC did not rise significantly. No treatment-related grade 3-5 toxicities. Efficacy: PFS6 – 15% and OS12 – 21%. CONCLUSIONS Induction of subclinical hypothyroidism is feasible and safe in rGBM with significant increases in plasma but not tumor HPC. Further tumor correlative data for the dose-escalated methimazole will be presented.
TIP-11. MOMENTUM-1: a multicenter, randomized, open-label, phase 2 study of [177Lu]Lu-DOTA-TATE in adults with progressive grade 1-3 meningioma (RTOG 3523)
Kurz, Sylvia C. , Rabbee, Nusrat, Wen, Patrick Y. , Kalapurakal, John A. , Bi, Lingge, Ivanidze, Jana , Cahill, Jennifer, Wen, Patrick Yung , Peereboom, David M. , Huang, Raymond Y. , Perry, Arie , Cahill, Jennifer, Johnson, Derek R. , Mehta, Minesh P. , Sulman, Erik P.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v422-v422

10.1093/neuonc/noaf201.1671 Get It

Abstract BACKGROUND While most meningiomas are classified as low-grade tumors with indolent behavior, a subset is characterized by a more aggressive clinical course and patients undergo repeated resections and courses of radiation. Once these therapies fail, prognosis is poor and progression-free survival (PFS) rates at 6 months (PFS-6) are estimated to only be 43.6% for WHO grade 1 and 38% for WHO grade 2/3 meningiomas. Effective medical therapies are limited. Somatostatin receptor 2 (SSTR2) is expressed in a majority of meningiomas and represents a suitable treatment target. [177Lu]Lu-DOTA-TATE (177Lu-Dotatate) is an SSTR2-targeted radioligand therapy, established as standard of care in the treatment of certain neuroendocrine tumors. Two ongoing non-randomized studies of 177Lu-Dotatate in meningiomas have reported encouraging efficacy compared to historical benchmarks. METHODS/STUDY DESIGN The MOMENTUM-1 study (RTOG 3523, NCT#06955169) is a multicenter, randomized, open-label study of 177Lu-Dotatate in adult patients with progressive intracranial WHO grade 1-3 meningiomas. Up to 130 eligible subjects are randomized in a 2:1 fashion to 177Lu-Dotatate at 7.4 GBq (200 mCi) every 4 weeks for 4 (+2 optional) doses or standard of care (SOC) medical therapy as defined by the protocol and deemed appropriate by the local investigator. Treatment responses are assessed by gadolinium-enhanced MRI brain and [68Ga]Ga-DOTA-TATE (68Ga-Dotatate) PET imaging. At time of progression, cross-over from the SOC to the interventional treatment arm is allowed. The primary endpoint is PFS. Secondary endpoints include PFS-6, OS-12, OS, response assessments (ORR, DCR), safety/tolerability, and patient-reported outcomes. RESULTS/CONCLUSION MOMENTUM-1 is a multicenter, randomized, open-label, phase II study of 177Lu-Dotatate in adult patients with progressive WHO grade 1-3 meningioma. This clinical trial is expected to start enrolling patients in the United States in the third quarter of 2025. Details on study design, eligibility criteria for subject enrollment and study site eligibility criteria will be presented.